The research, led by Hengyuan Zhang and Ziqing Zhang as co-first authors working with Jieqing Liu and colleagues at Huaqiao University in Quanzhou, China, began with a systematic evaluation of MLN4924’s antimelanogenic properties. The team used B16-F10 melanoma cells, a widely adopted murine model of melanocyte biology, stimulated with alpha-melanocyte stimulating hormone (α-MSH), the canonical upstream trigger of pigment production. When the cells were treated with MLN4924, melanin content dropped markedly. Because melanogenesis is driven principally by tyrosinase (TYR), the copper-containing enzyme that catalyzes the rate-limiting conversion of L-tyrosine into L-DOPA and onward into dopaquinone, the investigators measured tyrosinase activity directly. MLN4924 significantly reduced it. Importantly, the team’s control experiments suggested that this inhibition was likely a direct effect on the enzyme itself rather than an indirect consequence of antioxidant activity, a mechanism often invoked for plant-derived skin-lightening compounds. That distinction matters, because direct enzymatic inhibitors tend to produce more predictable and quantifiable dose-response behavior than compounds that merely quench the reactive oxygen intermediates involved in pigment chemistry.

The suppression did not stop at the level of enzyme kinetics. Using Western blotting and reverse transcription quantitative PCR, the researchers showed that MLN4924 downregulates the expression of the three members of the tyrosinase gene family—TYR itself, along with tyrosinase-related protein 1 (TYRP1) and tyrosinase-related protein 2 (TYRP2)—at both the protein and the mRNA levels in α-MSH-stimulated B16-F10 cells. These three glycoproteins reside in the membrane of melanosomes, the specialized lysosome-related organelles where melanin is synthesized, and they act in a coordinated enzymatic complex. TYRP1 and TYRP2 stabilize and modulate tyrosinase function and bias the pathway toward the production of eumelanin, the darker brown-black pigment most relevant to visible skin darkening. Reducing all three simultaneously, and doing so at the transcript level, indicates that MLN4924 is not merely degrading existing enzyme protein but is actively shutting down the transcriptional program that melanocytes deploy when instructed to make pigment.

That observation pointed the investigators toward the upstream signaling circuitry that controls those genes. The master regulator of melanocyte differentiation and pigment gene expression is microphthalmia-associated transcription factor (MITF), which binds the promoters of TYR, TYRP1, and TYRP2 and drives their expression. MITF activity itself is controlled by the cAMP-responsive element binding protein (CREB), a transcription factor activated when α-MSH binds the melanocortin 1 receptor, raising intracellular cAMP and prompting protein kinase A to phosphorylate CREB. In their mechanistic experiments, the team found that MLN4924 suppresses this CREB/MITF signaling axis, thereby cutting off the command signal that instructs the pigment genes to switch on. Crucially, the two other major pathways commonly implicated in pigmentation—the MAPK cascade and the cAMP pathway itself—were left largely unaffected. That selectivity is scientifically interesting because it suggests MLN4924 intervenes at a specific node rather than broadly blunting all signaling through the melanocyte, which could theoretically limit unwanted consequences on other cAMP- and MAPK-dependent cellular functions.

The specificity of the mechanism also speaks to a broader principle in drug development: compounds designed against one target frequently carry phenotypic activities that only surface when someone looks for them. MLN4924 was rationally engineered to block NAE, the enzyme that activates the ubiquitin-like protein NEDD8 for conjugation onto cullin-RING ligases. When neddylation is blocked, cullin-RING ligases fail to function, and their substrates—including the licensing factor Cdt1—accumulate aberrantly. In cancer cells, this triggers catastrophic DNA rereplication, checkpoint activation, apoptosis, and senescence, which is the basis of the drug’s antitumor effect. How exactly NAE inhibition feeds into the CREB/MITF axis in melanocytes remains an open question, and the present study does not fully resolve whether the effect depends on the drug’s canonical target or on an off-target interaction. Either way, the result demonstrates that neddylation biology, or the pharmacology of its inhibition, intersects with pigment cell regulation in a way that nobody had previously documented.

The in vivo component of the study provided the most striking translational evidence. When mice were exposed to UVB radiation and then treated with MLN4924, melanin accumulation in the ear tissue was markedly attenuated compared with irradiated controls. UVB-induced pigmentation is the standard experimental model for tanning, the process by which keratinocytes signal to melanocytes to ramp up melanin synthesis and transfer it as protective “umbrellas” over their nuclei. Blocking that response pharmacologically with a systemically administered enzyme inhibitor is a fundamentally different approach from the topical creams and botanical extracts that dominate the skin-lightening market. Encouragingly, the treatment appeared well tolerated: serum levels of GPT (glutamate pyruvate transaminase, a marker of liver injury) and BUN (blood urea nitrogen, a marker of kidney function) remained stable, indicating minimal systemic toxicity at the doses and schedule used. For a compound with cytotoxic potential in rapidly dividing cells, that tolerability signal in normal tissue is a meaningful early reassurance, though the authors and outside observers alike will note that far more extensive safety work would be required before any cosmetic or dermatological application.

The clinical context for hyperpigmentation research gives the finding real weight. Disorders such as melasma, post-inflammatory hyperpigmentation, lentigines, and generalized UV-induced darkening affect enormous numbers of people and carry significant psychosocial burden. The current pharmacopoeia is limited and imperfect. Hydroquinone, long the gold standard, has faced safety scrutiny and regulatory restrictions in several jurisdictions, with concerns about exogenous ochronosis and irritation. Alternatives such as arbutin, which releases hydroquinone slowly, glabridin from licorice extract, kojic acid, and azelaic acid offer modest efficacy, and many function primarily as direct tyrosinase inhibitors or antioxidants. A transcriptional approach that dampens the CREB/MITF axis would represent a mechanistically distinct strategy, hitting the pigment program at its source rather than at the terminal enzymatic step. The trade-off, of course, is that MITF is a pleiotropic factor—essential for melanocyte survival and, when dysregulated, implicated in melanoma progression—so systemic suppression would need to be approached with considerable caution.

That caution is amplified by MLN4924’s own dual personality in the oncology literature. Reviewers of the neddylation-inhibitor field have described the compound’s effects as double-edged, noting that while it kills many tumor cells, resistance mechanisms exist, and some contexts show paradoxical effects. The present study sidesteps the tumor-killing question by working in non-lethal dose ranges for its pigmentation assays, but any repurposing conversation will have to reconcile the dose that lightens skin with the dose that triggers DNA rereplication and cell death. It is conceivable that topical, low-dose delivery could achieve local tyrosinase and MITF suppression while avoiding systemic exposure, effectively converting a systemic oncology drug into a dermatological agent. That formulation challenge, along with studies in human melanocytes rather than murine B16-F10 cells, will be the obvious next steps for the field.

The study also contributes to a growing appreciation of the neddylation pathway in non-canonical contexts. Neddylation regulates cullin-RING ubiquitin ligases, which in turn control the degradation of hundreds of proteins involved in cell cycling, DNA repair, and signal transduction. The finding that blocking this pathway alters pigment gene transcription hints that one or more neddylation-dependent degradation targets may normally feed into or stabilize the CREB/MITF circuit. Identifying that substrate—or confirming a direct off-target interaction between MLN4924 and CREB pathway components—would transform the current phenomenological observation into a fully resolved molecular mechanism. The authors’ demonstration that MAPK and cAMP signaling remain intact narrows the search space considerably and provides a clean experimental framework for follow-up work.

For now, the study stands as a vivid example of drug repurposing serendipity and of how phenotypic screening can uncover biology that target-based drug design never anticipated. A compound built to starve tumors of protein degradation capacity has turned out to quiet the transcriptional orchestra that makes human skin dark. Whether MLN4924 or a derivative of it ever reaches a pharmacy shelf as a depigmenting agent will depend on formulation, safety, and efficacy studies that lie ahead. But the mechanistic map the Huaqiao University team has drawn—direct tyrosinase inhibition, coordinated suppression of the TYR/TYRP1/TYRP2 gene family, and selective silencing of the CREB/MITF axis with documented in vivo efficacy and stable liver and kidney markers—gives dermatologists and pigment biologists a new lead worth pursuing. The work was funded by the Quanzhou High Level Talent Innovation and Entrepreneurship Project, the Fujian Provincial Industry-University Cooperation Project, and the National Natural Science Foundation of China, with animal experiments conducted under institutional ethical approval.

Melanin, the naturally occurring pigment responsible for the coloration of skin, hair, and eyes in many species, plays a vital role in protecting cells from ultraviolet radiation damage. The synthesis of melanin—termed melanogenesis—occurs within melanocytes, specialized pigment-producing cells. Tyrosinase, a copper-containing enzyme, serves as the principal catalyst regulating this biosynthetic pathway by facilitating the hydroxylation of tyrosine to DOPA and dopaquinone, critical early steps in melanin formation. Dysregulation of this pathway manifests clinically in conditions ranging from hypopigmentation disorders like albinism to hyperpigmentation ailments such as vitiligo, melasma, and the malignant transformation seen in melanoma.

Despite melanin’s biological importance, excessive or uneven pigment production leads to significant cosmetic concerns and psychological distress for affected individuals, driving a considerable demand for effective therapeutic interventions. Current treatment options often rely on agents like hydroquinone, which, although widely used, carry limitations related to side effects and regulatory scrutiny. Addressing this therapeutic gap, the newly characterized compound ML233 emerges as a highly selective and effective tyrosinase inhibitor. Its ability to precisely target tyrosinase function represents a paradigm shift in modulating melanogenesis with the potential to circumvent the adverse effects associated with existing treatments.

The in-depth investigation into ML233’s mechanism of action was conducted by a multidisciplinary research team led by Dr. Romain Madelaine at MDI Biological Laboratory. Their comprehensive experimental study employed both in vivo and in vitro models, including live zebrafish and cultured melanocytes derived from murine and human sources. These biologically relevant systems enabled real-time observation of melanin reduction, revealing that ML233 robustly binds to the active site of tyrosinase, effectively blocking its enzymatic activity. Importantly, the compound achieved these results at remarkably low doses without eliciting significant cytotoxicity or systemic toxicity, underscoring its therapeutic promise.

Advancing beyond pigment modulation, the team explored ML233’s impact on oncogenic melanocytes due to melanoma’s notorious resistance to treatment. The study reports that ML233 substantially inhibited the proliferation of melanoma cells in vitro, notably affecting a specific subtype of human metastatic melanoma. This dual functionality as both a pigment regulator and a potential adjuvant cancer therapy agent suggests a versatile application pipeline. However, Dr. Madelaine emphasizes that ML233’s efficacy in melanoma treatment likely requires combination approaches and further rigorous investigation to delineate its clinical utility fully.

One of the most compelling aspects of ML233 lies in its chemical and pharmacological properties. The molecule exhibits high specificity for tyrosinase, minimizing off-target interactions—a frequent challenge in drug development that often leads to undesirable side effects. The structural analyses conducted indicate that ML233 possesses a unique binding conformation within the catalytic cleft of tyrosinase, potentially stabilizing the enzyme in an inactive form. Such specificity not only improves safety profiles but also enhances the potential success of long-term therapeutic regimes, a critical consideration given the chronic nature of pigmentation disorders.

An additional advantage is ML233’s efficacy at low concentrations, distinguishing it from conventional depigmentation agents that require higher dosages and pose increased risks of skin irritation and systemic exposure. This efficiency suggests potential cosmetic applications, where consumers increasingly demand safe, non-toxic alternatives for skin lightening and evening out pigmentary inconsistencies. MDI Bioscience has secured a patent for ML233, reflecting both its commercial viability and the scientific innovation it embodies.

The implications of this discovery extend beyond treatment paradigms. By elucidating the modulation of melanogenesis at a molecular level, ML233 provides a valuable probe for deeper biochemical investigations into melanocyte biology. Understanding tyrosinase’s interaction with inhibitors like ML233 can catalyze the development of next-generation therapies with greater precision and tailored pharmacodynamics. Moreover, ML233’s initial results in melanoma cell lines hint at broader oncology applications, potentially inspiring novel combinatorial strategies integrating enzymatic inhibition with immunotherapy or targeted molecular therapies.

While the initial data are promising, the research team and the broader scientific community acknowledge crucial questions remain regarding ML233’s long-term safety, pharmacokinetics, and effectiveness across diverse patient populations. Preclinical studies focused on toxicity profiling, dose optimization, and delivery mechanisms will be critical precursors to human clinical trials. Furthermore, unraveling the molecular determinants that confer susceptibility or resistance to ML233 within various melanoma subtypes could inform personalized medicine approaches and rational drug design.

It is also noteworthy that this research was supported by the National Institute of General Medical Sciences, a component of the NIH, highlighting the importance of sustained funding for translational biomedical research. Collaborations between academic institutions, biotechnology entities, and regulatory agencies will be essential to navigate ML233 from promising laboratory findings to approved clinical interventions.

In conclusion, ML233 stands as a beacon of innovation in the field of dermatology and cancer therapy, offering a novel mechanism to regulate melanin biosynthesis with unprecedented precision and safety. MDI Bioscience’s pioneering work not only charts new territories in pigment-related disease management but also opens avenues for integrating chemical biology tools into clinical strategies. Future research endeavors dedicated to expanding ML233’s therapeutic scope will be eagerly anticipated by clinicians, researchers, and patients alike, heralding a new era of effective and well-tolerated treatments for some of the most challenging skin conditions.

Subject of Research: Cells

Article Title: The small molecule ML233 is a direct inhibitor of tyrosinase function

News Publication Date: 28-Mar-2025

Web References:
https://www.nature.com/articles/s42003-025-07973-5
http://dx.doi.org/10.1038/s42003-025-07973-5

Keywords: Melanin, Enzyme inhibitors, Inhibitory effects, Chemical biology, Cancer treatments, Diseases and disorders, Human health